|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Accounts and grants receivable, net | ||||||||||||||||||||
| Related party receivables, net | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total related party receivables, net | ||||||||||||||||||||
| Grant receivable | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use assets - operating leases | ||||||||||||||||||||
| Right of use assets - finance leases | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Convertible note receivable | ||||||||||||||||||||
| Other long-term prepaid assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Loans due to Juvenescence, net of debt issuance costs | ||||||||||||||||||||
| Current portion of operating lease liabilities | ||||||||||||||||||||
| Current portion of finance lease liabilities | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Convertible Note, net | ||||||||||||||||||||
| Tranche liability | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Total other current liabilities | ||||||||||||||||||||
| Insurance premium liability and other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Loans due to Juvenescence, net of current portion | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Warrant liability, non-current | ||||||||||||||||||||
| Convertible Note, net | ||||||||||||||||||||
| Operating lease liabilities, net of current portion | ||||||||||||||||||||
| Finance lease liabilities, net of current portion | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Redeemable convertible preferred stock, $0.01 par value; 10,000 shares authorized; zero and 3,438 shares issued and outstanding at December 31, 2024 and 2023, respectively; Liquidation preference of zero and $36,982 at December 31, 2024 and 2023, respectively | ||||||||||||||||||||
| Redeemable convertible preferred stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total redeemable convertible preferred stock, $0.01 par value; 10,000 shares authorized; zero and 3,438 shares issued and outstanding at December 31, 2024 and 2023, respectively; Liquidation preference of zero and $36,982 at December 31, 2024 and 2023, respectively | ||||||||||||||||||||
| Stockholders’ equity (deficit): | ||||||||||||||||||||
| Series A convertible preferred stock, $0.0001 par value, 5,000 shares authorized; zero and 965 issued and outstanding at June 30, 2026 and December 31, 2025, respectively; liquidation preference of $0 and $5,000 at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Common stock, $0.0001 par value, 125000000 and 40,000 shares authorized; 25,400 and 10,767 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total Serina Therapeutics, Inc. stockholders’ (deficit) equity | ||||||||||||||||||||
| Noncontrolling deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY (DEFICIT) | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||||||||||||||
Loading...
